Monitoring cognitive impairment through speech

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings.

@@alt

A biomarker for clinical research

Paper-based cognitive assessments are slow, subjective and often coarse. Winterlight has developed a speech-based cognitive assessment that analyzes short snippets of speech and uses AI to objectively measure cognition via hundreds of markers in speech and language. Winterlight can support clinical trials and studies for a wide range of central nervous system disorders.

Work with us
@@alt

Tracking cognitive wellness in senior care

It is challenging to care for seniors with complex medical needs and frequently with cognitive impairments. Combined with your existing health data, we identify seniors at-risk of cognitive or functional decline. Our assessment can help you provide better proactive care at a time when it is most needed to have the greatest impact on the health and happiness of your residents.

Reach us here
@@alt

Winterlight’s Healthy Aging Study

We are building better tools so that we can identify risk for dementia more quickly and at an earlier age. This will researchers to better understand the disease and work towards a cure. If you are healthy and 50 years or older in the Greater Toronto Area, we would like your help on learning the effect of the aging process on the brain.

Tell me more

Developed in partnership with:



What's new

January 2018

Winterlight Labs is featured on CTV News, discussing its partnership with Revera

Winterlight will be piloting its speech-based cognitive assessment at one of Revera's senior care homes in Toronto with 50 participants over a 6 month period. This pilot was funded via the Ontario Centres of Excellence (OCE) Health Technology Fund (HTF).

READ
January 2018

Winterlight Labs participates in a J&J feasibility study

The research will evaluate Winterlight's proprietary technology for analyzing voice samples obtained from Janssen Research & Development's ongoing clinical trials in Alzheimer's and neurodegenerative diseases.

READ
August 2017

Winterlight Labs secures additional seed funding ($1,000,000) from American investors

Winterlight Labs has closed $1,000,000 in additional seed funding from Grey Sky Venture Partners (GSVP), based on Bellevue Washington. In total, Winterlight Labs has raised $1.5 million.

READ

Get in touch

Mailing Address

Winterlight Labs Inc.
Attn: Liam Kaufman
JLABS @ Toronto,
MaRS DD, West Tower
661 University Avenue
Suite 1300
Toronto, ON, M5G 0B7

Send us a message